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Introduction {#sec1}
============

The thyroid axis plays a major role in the regulation of energy balance and metabolism ([@bib16], [@bib58], [@bib29], [@bib37]). One of the main features of patients with thyroid dysfunction is the concurrence of hyperphagia and weight loss in hyperthyroidism ([@bib49], [@bib29], [@bib37]). These beneficial effects have led to the development of selective thyroid hormone (TH) mimetics ([@bib15]) as powerful new tools against atherosclerosis and obesity.

The classical view assumes that most physiological effects of THs (triiodothyronine \[T3\] and its prohormone, thyroxine \[T4\]) are exerted at the peripheral level ([@bib49], [@bib50]). However, recent evidence indicates that TH actions on energy metabolism are centrally mediated ([@bib16], [@bib58], [@bib29], [@bib37]). THs modulate food intake through their action in the arcuate nucleus of the hypothalamus (ARC) ([@bib11], [@bib55], [@bib54]). THs also modulate energy expenditure (EE). This effect has been conventionally ascribed to their direct action on peripheral tissues, such as brown adipose tissue (BAT) and skeletal muscle ([@bib49], [@bib7]), but recent evidence has challenged that view. Indeed, T3 acts in the ventromedial nucleus of the hypothalamus (VMH) to regulate thermogenesis in BAT ([@bib28]) and browning of white adipose tissue (WAT) ([@bib32]). The central effect of THs has also been implicated in the regulation of endogenous glucose production and insulin sensitivity ([@bib16]). Of note, selective interference with the transmission of the sympathetic and parasympathetic nervous system (SNS and PSNS) completely abolishes the effect of central T3 on glucose homeostasis ([@bib16]). However, it is totally unknown whether central actions of THs regulate peripheral lipid metabolism. The aims of this study were (1) to determine whether central THs regulate peripheral lipid metabolism, (2) to characterize the molecular mechanisms leading to that effect, and (3) to investigate whether those actions were part of a coordinated response integrating lipid homeostasis and energy balance at the whole-body level.

Results {#sec2}
=======

Hyperthyroidism Is Associated with Tissue-Specific Regulation of the Lipogenesis Pathway {#sec2.1}
----------------------------------------------------------------------------------------

T4-treated rats showed decreased body weight despite hyperphagia and increased circulating levels of T4 and T3 ([Figure S1](#mmc1){ref-type="supplementary-material"}A). In the liver (but not muscle, WAT, or BAT), the global effect of hyperthyroidism promoted de novo lipogenesis, as indicated by the decreased phosphorylated AMP-activated protein kinase (pAMPK) and acetyl-CoA carboxylase (pACC) and increased fatty acid synthase (FAS), as well as increased hepatic Oil Red O staining and triglyceride (TG) levels ([Figures S1](#mmc1){ref-type="supplementary-material"}B--S1D).

Central T3 Regulation of Lipid Metabolism in Liver and BAT {#sec2.2}
----------------------------------------------------------

Chronic ICV (intracerebroventricular) T3 induced weight loss and a slight decrease in thyrotropin-releasing hormone (TRH, codified by *Trh*) mRNA in the paraventricular nucleus of the hypothalamus (PVH), but altered neither feeding nor circulating thyroid-stimulating hormone (TSH), nor T4 and T3 levels ([Figure S1](#mmc1){ref-type="supplementary-material"}E). The weight-reducing effect of central T3 was recapitulated in hypothyroid rats (data not shown). ICV administration of T3 promoted a comparable pattern of protein expression in peripheral tissues to that observed in hyperthyroid rats ([Figure 1](#fig1){ref-type="fig"}A). Accordingly, central administration of T3 increased hepatic lipid and TG content ([Figures 1](#fig1){ref-type="fig"}B and 1C), de novo TG synthesis ([Figure 1](#fig1){ref-type="fig"}D), as well as the hepatic activity and/or mRNA expression of phosphatidate phosphatase 1 (LIPIN1, codified by *Lpin1*) and diacylglycerol O-acyl-transferase 1 (DGAT1, codified by *Dgat1*), enzymes catalyzing the formation of diglyceride (DAG) and TG, respectively ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Of note, no changes were found in either lipid oxidative gene expression, such as the liver isoform of carnitine palmitoyltransferase 1a (CPT1a, codified by *Cpt1a*), nuclear respiratory factor 1 (NFR1, codified by *Nrf1*), and peroxisome-proliferator-activated receptor-gamma co-activator 1 alpha and beta (PGC1α and β, codified by *Ppargc1a* and *Ppargc1b*, respectively) ([Figure S1](#mmc1){ref-type="supplementary-material"}G); liver lipid oxidation rate and mitochondrial oxygen consumption *in vivo* and *in vitro* ([Figure S1](#mmc1){ref-type="supplementary-material"}H); or serum ketone bodies ([Figure S1](#mmc1){ref-type="supplementary-material"}I).Figure 1Effect of Central THs on Liver and BAT(A) Protein levels of the AMPK pathway in the liver, WAT, muscle, and BAT (n = 8--17 rats/group).(B and C) Oil Red O (20×; scale bar, 100 μm) staining analysis (B) and TG levels in the liver (n = 8--9 rats/group) (C).(D) \[^3^H\]-acetate incorporation into TGs in the liver (n = 6--7 rats/group).(E) mRNA levels of BAT genes (n = 5--7 rats/group).(F) Protein levels of UCP1 in the BAT (n = 14 rats/group).(G) ^18^F-FDG uptake analysis (n = 8 rats/group).(H) Lipid oxidation rate, oxygen consumption rate in the BAT, and oxygen consumption in BAT mitochondria (n = 6--7 rats/group).(I) Electron microscopy images (4,000×; scale bar, 10 μm) and quantification of lipid droplet (LD) and mitochondria number/area unit, size, and ultrastructure in the BAT (n = 4 rats/experimental group, 30 images/animal).(J) Cumulative EE, RQ, and LA (n = 5 rats/group).(K) c-FOS images (10×; scale bar, 50 μm) and staining analysis in the dorsal nucleus of the vagus (DMV) (n = 4 rats/group, 9--32 sections/animal) of rats ICV treated with vehicle or T3.(L) Protein levels of the AMPK pathway in the liver of sham or VGX rats ICV treated with vehicle or T3 (n = 11--14 rats/group).(M) Sympathetic nerve activity (SNA) in the BAT (n = 8--11 rats/group) of rats ICV treated with vehicle or T3.(N) Protein levels of the AMPK pathway in the BAT of rats ICV treated with vehicle or T3 and s.c. treated with SR59230A (n = 7 rats/group).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus vehicle ICV. \#p \< 0.05 T3 ICV vehicle s.c. versus T3 ICV SR59230A s.c. Data are expressed as mean ± SEM. The bands in gels from (A), (F), (L), and (N) have been spliced from the same original gels. CC, central canal; HN, hypoglossal nucleus; ND, non-detected; SUV, standardized uptake value. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Analysis of BAT after central T3 infusion revealed increased mRNA expression of thermogenic markers, such as uncoupling protein 1 and 3 (UCP1 and 3, codified by *Ucp1* and *Ucp3*, respectively), PGC1α, and fibroblast growth factor 21 (FGF21, codified by *Fgf21*), as well as protein levels of UCP1 ([Figures 1](#fig1){ref-type="fig"}E and 1F). The effect of central T3 on BAT UCP1 expression was recapitulated in hypothyroid rats (data not shown). Notably, the effect of T3 on FGF21 was specific for BAT because no changes were found in either its hepatic mRNA expression (vehicle ICV, 100% ± 37.0%; T3 ICV, 74.13% ± 22.4%) or circulating levels (vehicle ICV, 93.54 ± 1.98 U/mL; T3 ICV, 93.04 ± 1.44 U/mL). Central T3 induced a marked activation of brown fat, as indicated by a higher 2-^18^F-fluoro-2-deoxy-2-glucose (^18^F-FDG) uptake analyzed by positron emission tomography-computed tomography (PET-CT) ([Figure 1](#fig1){ref-type="fig"}G), associated with increased lipid oxidation and mitochondrial oxygen consumption ([Figure 1](#fig1){ref-type="fig"}H). Electron microscopy analysis of BAT showed decreased mitochondrial density and lipid droplet (LD) content, whereas the size of the mitochondria was increased ([Figure 1](#fig1){ref-type="fig"}I), which is indicative of activation of BAT ([@bib51]). A slight, but not significant, decrease in BAT lipogenesis rate was found after T3 ICV treatment with no variations in TG and fatty acid (FA) concentration ([Figure S1](#mmc1){ref-type="supplementary-material"}J). After central administration of T3, rats showed increased EE and decreased respiratory quotient (RQ, indicating increased lipid utilization), consistently with enhanced BAT-dependent oxidation fueled mainly by FA ([Figure 1](#fig1){ref-type="fig"}J), as well as reduced locomotor activity (LA) ([Figure 1](#fig1){ref-type="fig"}J). Overall, our results indicate that the effect of central T3 on liver and BAT is mediated via a direct action of THs in the central nervous system (CNS). This was further substantiated by the absence of changes in liver and BAT AMPK pathway following intraperitoneal (i.p.) administration of T3 at the same dose used in the ICV injections ([Figure S1](#mmc1){ref-type="supplementary-material"}K).

The Autonomic Nervous System Mediates Central T3 Actions on Lipid Metabolism in Liver and BAT {#sec2.3}
---------------------------------------------------------------------------------------------

We examined the contribution of the autonomic nervous system (ANS) in mediating the regulation of liver and BAT lipid metabolism following central administration of T3. Previous evidence demonstrated that T3 ICV increases c-FOS expression in the raphe pallidus (RPa) and the inferior olive (IO) nuclei ([@bib28]). Our data showed that central T3 administration induced c-FOS expression in the dorsal nucleus of the vagus (DMV) ([Figure 1](#fig1){ref-type="fig"}K; normalized data, vehicle ICV, 100% ± 20.6%; T3 ICV, 812.75% ± 101.90%, p \< 0.001). Therefore, we sought to determine whether the effect of central T3 on hepatic lipid metabolism involved vagal innervation. Thus, we compared the effect of T3 in vagotomized (VGX) and sham rats. ICV T3 administration decreased body weight (but not food intake) in sham and VGX rats ([Figure S1](#mmc1){ref-type="supplementary-material"}L). However, vagotomy was sufficient to blunt T3-mediated induction of hepatic AMPK pathway ([Figure 1](#fig1){ref-type="fig"}L), as well as the mRNA expression of LIPIN1 and DGAT1 ([Figure S1](#mmc1){ref-type="supplementary-material"}L) and liver FA content (data not shown). These findings indicate that the vagus nerve mediates the effects of central T3 on liver lipid metabolism.

T3 ICV increased BAT sympathetic nerve traffic ([Figure 1](#fig1){ref-type="fig"}M). Pharmacological inactivation of β3 adrenoceptors (β3-ARs) by subcutaneous administration of the specific antagonist SR59230A ([@bib28], [@bib31]) prevented the effect on body weight associated with central administration of T3 without interfering with the feeding response (body weight change: vehicle ICV vehicle subcutaneously \[s.c.\], 19.57 ± 2.88 g; T3 ICV vehicle s.c., 10.25 ± 1.91 g, p \< 0.01 versus vehicle ICV vehicle s.c.; T3 ICV SR59230A s.c., 16.75 ± 2.34 g, p \< 0.05 versus T3 ICV vehicle s.c.; food intake: vehicle ICV vehicle s.c., 29.18 ± 1.09 g; T3 ICV vehicle s.c., 27.34 ± 0.94 g; T3 ICV SR59230A s.c., 30.50 ± 0.70 g). Furthermore, SR59230A blocked the T3-mediated activation of the AMPK pathway in BAT ([Figure 1](#fig1){ref-type="fig"}N). No changes were detected in T3-induced lipogenesis pathway in liver ([Figure S1](#mmc1){ref-type="supplementary-material"}M). Overall, these data indicate that T3 acts in the CNS to regulate thermogenesis and AMPK signaling in BAT (but not in liver) via increased SNS activation of the β3-AR.

Central T3 Regulates Lipid Uptake in BAT {#sec2.4}
----------------------------------------

To determine how central T3-mediated increase in hepatic lipogenesis impacts FA uptake in peripheral tissues, T3 was ICV injected to rats pre-treated with ^14^C-oleate. Analysis of serum revealed a more rapid accumulation of ^14^C in the T3-treated rats ([Figure 2](#fig2){ref-type="fig"}A), with a shift toward the radiolabel being more abundant in the aqueous rather than in the lipid phase ([Figure 2](#fig2){ref-type="fig"}B). This suggested that FA removal from serum was increased alongside elevated β-oxidation of lipids, driving labeled water-soluble metabolites into the circulation. Central T3 increased ^14^C uptake in both liver and BAT per gram of tissue, where BAT exhibited the highest uptake rate ([Figure 2](#fig2){ref-type="fig"}C). However, when correcting for total organ weight, the liver had a significantly larger contribution to total lipid clearance ([Figure 2](#fig2){ref-type="fig"}D). Of note, liver displayed a significant increase in ^14^C-labeled TGs, indicating that FAs were being incorporated into newly synthesized TGs ([Figure 2](#fig2){ref-type="fig"}E), in keeping with the expression data of AMPK pathway, hepatic lipid, TG content, and lipogenesis ([Figures 1](#fig1){ref-type="fig"}A--1D), as well as LIPIN1 and DGAT1 ([Figure S1](#mmc1){ref-type="supplementary-material"}F). In contrast, the tendency of reduced lipogenesis in BAT ([Figure S1](#mmc1){ref-type="supplementary-material"}J), together with increased oxidative/thermogenic gene expression and elevated EE, glucose uptake, and mitochondrial and lipid droplet changes ([Figures 1](#fig1){ref-type="fig"}E--1J), suggests that the lipids being taken up by BAT serve as fuel for thermogenesis. Comparably, no regulation of ^14^C uptake was detected in WAT after central T3 administration in ^14^C-oleate-infused rats ([Figures 2](#fig2){ref-type="fig"}C and 2D), indicating that this treatment had a net EE rather than energy storage effect.Figure 2Effect of T3 within the VMH on Liver and BAT(A and B) ^14^C levels in serum (A) and lipid or aqueous phases (B) of rats ICV treated with vehicle or T3 (n = 9 rats/group).(C--E) Total ^14^C content (C); ^14^C content corrected by tissue/organ weight in the liver, BAT, and WAT (D); and ^14^C TG content in serum, liver, and BAT (E) of rats ICV treated with vehicle or T3 (n = 9 rats/group).(F) Body weight change, food intake, and body mass change of rats treated in the VMH with vehicle or T3 (n = 16--17 rats/group; 7 rats/group for NMR analysis).(G--I) Protein levels of UPC1 in the BAT and the AMPK pathway in the BAT and liver of rats treated in the VMH with vehicle or T3 (n = 14 rats/group).(J and K) Oil Red O (20×; scale bar, 100 μm) staining analysis (J) and TG levels in the liver of rats treated in the VMH with vehicle or T3 (n = 8--9 rats/group) (K).(L--N) Protein levels of the AMPK pathway in the BAT (L) and liver (M) and UCP1 in the BAT (N) of rats treated in the VMH with adenoviruses encoding GFP or TR-DN (n = 8 rats/group).(O and P) Oil Red O (20×; scale bar, 100 μm) staining analysis (O) and TG levels in the liver of rats treated in the VMH with adenoviruses encoding GFP or TR-DN (n = 8 rats/group) (P).(Q) Protein levels of the AMPK pathway in the liver of sham or VGX rats treated in the VMH with vehicle or T3 (n = 8 rats/group).(R and S) Oil Red O (20×; scale bar, 100 μm) staining analysis (R) and TG levels in the liver of sham or VGX rats treated in the VMH with vehicle or T3 (n = 8 rats/group) (S).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus vehicle ICV, vehicle VMH, sham, or GFP. Data are expressed as mean ± SEM. The bands in gels from (H), (I), (L)--(N), and (Q) have been spliced from the same original gels. See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

T3 in the VMH Regulates Lipid Metabolism in Liver and BAT {#sec2.5}
---------------------------------------------------------

Next, we performed administration of T3 into the VMH or the ARC. The correct position of the cannulae was verified by histological examination ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2B). In addition, when compared with acute injections in the VMH, chronic cannulae did not increase the immunoreactivity or the protein levels of inflammation markers in the VMH, such as ionized calcium-binding adaptor molecule 1 (IBA1), interleukin 6 (IL-6), nuclear factor kappa-light-chain enhancer of activated B cells (NFκB), and phosphorylated IκB kinase (pIKK) ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2D).

T3 in the VMH promoted a feeding-independent weight loss and reduced adiposity ([Figure 2](#fig2){ref-type="fig"}F), associated with increased UCP1 protein levels in BAT ([Figure 2](#fig2){ref-type="fig"}G). This response was maintained when T3 was given for longer periods of time ([Figure S2](#mmc1){ref-type="supplementary-material"}E), indicating that this action likely contributes to hyperthyroidism-induced weight loss. We found that VMH T3 increased pAMPK and pACC in BAT ([Figure 2](#fig2){ref-type="fig"}H). Conversely, it induced a downregulation of the AMPK pathway in the liver ([Figure 2](#fig2){ref-type="fig"}I), alongside increased lipid and TG accretion ([Figures 2](#fig2){ref-type="fig"}J and 2K), resembling the effects observed after ICV T3. To control the specificity, we analyzed "missed" T3 injections in "VMH neighboring" areas, without affecting the VMH; no changes in the AMPK pathway in liver and BAT were detected ([Figure S2](#mmc1){ref-type="supplementary-material"}F). When T3 was administered into the ARC, there was a tendency for increased body weight at the end of the treatment, associated with hyperphagia, but no alterations in body composition ([Figure S2](#mmc1){ref-type="supplementary-material"}G) or UCP1 protein levels in BAT ([Figure S2](#mmc1){ref-type="supplementary-material"}H). Notably, no effects were found either in liver or BAT lipogenic program ([Figure S2](#mmc1){ref-type="supplementary-material"}I).

To test this further, we ablated TH receptor (TR) action in the VMH of euthyroid and hyperthyroid rats by delivery of adenoviruses encoding a dominant-negative mutant of TR (TR-DN) or GFP ([@bib28]). The infection efficiency was demonstrated by assaying GFP in the VMH (similar to [Figure S3](#mmc1){ref-type="supplementary-material"}A). Injection of TR-DN into the VMH of euthyroid rats exerted opposite effects on liver and BAT AMPK pathway compared to those evoked by T3 administration in this same nucleus ([Figure S2](#mmc1){ref-type="supplementary-material"}J). Of note, when adenoviruses harboring TR-DN targeted the VMH of hyperthyroid rats, they induced feeding-independent weight gain (body weight change: hyperthyroid GFP, 8.23 ± 2.0 g; hyperthyroid TR-DN, 15.0 ± 1.51 g, p \< 0.01; food intake: hyperthyroid GFP, 31.35 ± 1.63 g; hyperthyroid TR-DN, 31.4 ± 1.44 g) and blunted the effect of hyperthyroidism on BAT metabolism ([Figures 2](#fig2){ref-type="fig"}L and 2M), but increased liver AMPK signaling ([Figure 2](#fig2){ref-type="fig"}N) and subsequently reduced hepatic lipid ([Figure 2](#fig2){ref-type="fig"}O) and TG content ([Figure 2](#fig2){ref-type="fig"}P). Next, we examined the effect of vagotomy on the actions of VMH T3 on liver and BAT. Our results were consistent with those obtained with ICV T3 injection, as vagotomy totally reverted the effects of VMH T3 on hepatic AMPK pathway ([Figure 2](#fig2){ref-type="fig"}Q), lipid content ([Figure 2](#fig2){ref-type="fig"}R), and TG levels ([Figure 2](#fig2){ref-type="fig"}S), without impacting either body weight ([Figures S2](#mmc1){ref-type="supplementary-material"}K and S2L) or UCP1 ([Figure S2](#mmc1){ref-type="supplementary-material"}M) in BAT. Altogether, these data demonstrate that the effect of T3 on the PSNS and liver metabolism originates from the TRs in the VMH.

Central Effects of T3 on Liver and BAT Depend on AMPK in the VMH {#sec2.6}
----------------------------------------------------------------

Hypothalamic AMPK mediates the central effect of T3 on BAT thermogenesis ([@bib28]). To elucidate the contribution of AMPK activity in the hypothalamus to the lipogenic program in liver and BAT, adenoviruses encoding either a dominant-negative isoform of AMPKα (AMPKα-DN) ([@bib28], [@bib31]) or GFP were injected into the VMH of euthyroid rats. The infection efficiency was demonstrated by assaying hypothalamic expression of GFP into the VMH ([Figure S3](#mmc1){ref-type="supplementary-material"}A). Treatment with AMPKα-DN adenoviruses induced a feeding-independent weight loss ([Figure 3](#fig3){ref-type="fig"}A) associated with increased UCP1 levels in BAT ([Figure 3](#fig3){ref-type="fig"}B). Of note, inhibition of AMPKα recapitulated the effects of T3 injection in the VMH, namely increased AMPK signaling in BAT ([Figure 3](#fig3){ref-type="fig"}C) and decreased AMPK signaling and elevated lipid and TG content in the liver ([Figures 3](#fig3){ref-type="fig"}D--3F). Thus, we hypothesized that the central effect of T3 on hepatic and BAT metabolism was mediated by specific inhibition of AMPK in the VMH. To test this, adenoviruses encoding either a constitutively active isoform of AMPKα (AMPKα-CA) ([@bib28], [@bib31]) or GFP were injected into the VMH of hyperthyroid rats. Overexpression of AMPKα-CA in the VMH was accompanied by weight gain in hyperthyroid rats, but not in euthyroid rats, with no alteration in feeding ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These effects were associated with reversal of the hyperthyroidism-induced effect on the lipogenic de novo pathway in liver and BAT ([Figures 3](#fig3){ref-type="fig"}G and 3H). To test this, AMPKα-CA adenoviruses were administered into the VMH of rats centrally treated with T3. Our data showed that constitutive activation of AMPK in the VMH reversed the effect of central T3 on body weight in a feeding-independent manner ([Figure S3](#mmc1){ref-type="supplementary-material"}C) and normalized UCP1 levels in BAT ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Moreover, AMPKα-CA in the VMH reversed the effects of central T3 on the AMPK pathway in liver and BAT ([Figures 3](#fig3){ref-type="fig"}I and 3J). Together, these results are consistent with the observation that a reduction of AMPK activity in the VMH mediates the central effects of THs on liver and BAT lipid metabolism.Figure 3Effect of Activation of AMPK within the VMH on the Central Actions of THs on Liver and BAT(A) Body weight change and food intake of rats treated in the VMH with adenoviruses encoding GFP or AMPKα-DN (n = 23--25 rats/group).(B--D) Protein levels of UCP1 in the BAT (B) and the AMPK pathway in the BAT (C) and liver (D) of rats treated in the VMH with adenoviruses encoding GFP or AMPKα-DN (n = 12--13 rats/group).(E and F) Oil Red O (20×; scale bar, 100 μm) staining analysis (E) and TG levels in the liver of rats treated in the VMH with adenoviruses encoding GFP or AMPKα-DN (n = 12--14 rats/group) (F).(G and H) Protein levels of the AMPK pathway in the liver (G) and BAT (H) of euthyroid and hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or AMPKα-CA (n = 7 rats/group).(I and J) Protein levels of the AMPK pathway in the liver (I) and BAT (J) of rats ICV treated with vehicle or T3 and treated in the VMH with adenoviruses encoding GFP or AMPKα-CA (n = 7 rats/group).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus GFP, euthyroid GFP, and vehicle ICV GFP; \#p \< 0.05, \#\#p \< 0.01, \#\#\#p \< 0.001, hyperthyroid GFP versus hyperthyroid AMPKα-CA or T3 ICV GFP versus T3 ICV AMPKα-CA. Data are expressed as mean ± SEM. The bands in gels from (B)--(D) and (G)--(J) have been spliced from the same original gels. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

Ablation of AMPKα1 in SF1 Neurons of the VMH Fully Recapitulates the Effect of Central T3 on BAT and Liver Metabolism {#sec2.7}
---------------------------------------------------------------------------------------------------------------------

It is known that steroidogenic factor 1 (SF1) neurons in the VMH play a major role in the regulation of energy balance by integrating peripheral signals (such as leptin, insulin, and estradiol) ([@bib12], [@bib60], [@bib9]) and central mediators (such as glutamate) ([@bib52]). Moreover, it has been reported that SF1 neurons project to autonomic centers modulating the SNS ([@bib27], [@bib9]). Given that T3 selectively regulates hypothalamic AMPKα1 (but not AMPKα2) expression and activity ([@bib28]), we generated an SF1 neuron-specific AMPKα1 mouse line (SF1-Cre AMPKα1^flox/flox^) by crossing floxed AMPKα1 mice ([@bib38]) and SF1-Cre mice, which express Cre recombinase under SF1 promoter, hence targeting subsets of neurons of the VMH ([@bib12]). Allele-specific PCR demonstrated that we successfully deleted AMPKα1 in the SF1 population of the VMH ([Figure S4](#mmc1){ref-type="supplementary-material"}A). Deletion of AMPKα1 was observed in tissues in which SF1 is also endogenously expressed, such as the adrenal gland, testis, and pituitary ([Figure S4](#mmc1){ref-type="supplementary-material"}A). In contrast, other tissues examined, including the cerebellum, cerebral cortex, and liver, did not show Cre-mediated recombination ([Figure S4](#mmc1){ref-type="supplementary-material"}A). In addition, we also measured AMPKα1 levels using qRT-PCR and found significantly decreased expression of AMPKα1 in the VMH, but not in the cerebral cortex ([Figure S4](#mmc1){ref-type="supplementary-material"}B) or liver (data not shown). To further verify AMPKα1 deletion in the SF1 population of the VMH, we performed in situ hybridization using an oligo-labeled probe against the deleted sequence. AMPKα1 mRNA (codified by *Prkaa1*) was reduced specifically in the VMH of SF1-Cre AMPKα1^flox/flox^ mice, confirming the specific AMPKα1 deletion in SF1 neurons of the VMH ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Western blot analysis of the AMPK pathway in the VMH showed decreased pAMPK, AMPKα1 (but not AMPKα2), and pACC protein content ([Figure S4](#mmc1){ref-type="supplementary-material"}D). On the other hand, FAS expression was elevated in the VMH of SF1-Cre AMPKα1^flox/flox^ mice ([Figure S4](#mmc1){ref-type="supplementary-material"}D).

SF1-Cre AMPKα1^flox/flox^ mice showed a feeding-independent decrease in body weight and adiposity ([Figures 4](#fig4){ref-type="fig"}A--4C), coupled with increased EE ([Figure 4](#fig4){ref-type="fig"}D) and activation of the brown fat, as demonstrated by a higher ^18^F-FDG uptake analyzed by PET-CT ([Figure 4](#fig4){ref-type="fig"}E), BAT temperature ([Figure 4](#fig4){ref-type="fig"}F), and BAT sympathetic nerve traffic ([Figure 4](#fig4){ref-type="fig"}G). Of note, pharmacological inactivation of β3-AR with SR59230A reverted (in a feeding-independent manner) the weight loss and increased BAT temperature of SF1-Cre AMPKα1^flox/flox^ mice ([Figures S4](#mmc1){ref-type="supplementary-material"}E--S4G). Molecular analysis of BAT showed elevated mRNA and/or protein expression of all the thermogenic markers examined ([Figures 4](#fig4){ref-type="fig"}H and 4I). In relation to the liver, SF1-Cre AMPKα1^flox/flox^ mice showed decreased activation of the AMPK pathway ([Figure 4](#fig4){ref-type="fig"}J), which was indicative of increased lipogenesis, as demonstrated by augmented hepatic TG content ([Figure 4](#fig4){ref-type="fig"}K). Overall, this evidence indicated that deletion of AMPKα1 in SF1 neurons of the VMH fully recapitulated the central effect of THs on BAT and liver metabolism.Figure 4Effect of Deletion of AMPKα1 in SF1 Neurons in Liver and BAT(A--C) Body weight (A), food intake (B), and fat depot mass (C) of SF1-Cre AMPKα1^flox/flox^ mice (n = 15--25 mice/group).(D) Cumulative EE of SF1-Cre AMPKα1^flox/flox^ mice (n = 5--6 mice/group).(E) ^18^F-FDG uptake analysis of SF1-Cre AMPKα1^flox/flox^ mice (n = 5--6 mice/group).(F) Infrared thermal images and quantification of temperature of BAT skin area of SF1-Cre AMPKα1^flox/flox^ mice (n = 9--23 mice/group).(G) BAT SNA of SF1-Cre AMPKα1^flox/flox^ mice (n = 7--8 mice/group).(H) mRNA levels of BAT genes of SF1-Cre AMPKα1^flox/flox^ mice (n = 8 mice/group).(I) Protein levels of thermogenic markers and proteins involved in lipolysis in the BAT of SF1-Cre AMPKα1^flox/flox^ mice (n = 7 mice/group).(J) Protein levels of AMPK pathway in the liver of SF1-Cre AMPKα1^flox/flox^ mice (n = 7 mice/group).(K) TG levels in the liver of SF1-Cre AMPKα1^flox/flox^ mice (n = 9--10 mice/group).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, SF1-Cre AMPKα1^flox/flox^ versus AMPKα1^flox/flox^. Data are expressed as mean ± SEM. The bands in gels from (I) and (J) have been spliced from the same original gels. iWAT, inguinal WAT; gWAT, gonadal WAT; vWAT, visceral WAT. See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

THs Alter Hypothalamic Lipid Composition and Reduce Ceramide Levels {#sec2.8}
-------------------------------------------------------------------

To assess the molecular mechanisms mediating the effects of TH-induced decrease in AMPK in the VMH, we performed several experiments. Given that AMPK is one of the main upstream regulators of lipid metabolism ([@bib23], [@bib30]), we assayed hypothalamic lipid composition. We found no alterations in any of the saturated and unsaturated FAs measured in either the hypothalamus or cortex of hyperthyroid rats when compared with euthyroid rats ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Comparative multivariate analysis of the data identified clear differences in complex lipid profiles in the hypothalamus ([Figure S5](#mmc1){ref-type="supplementary-material"}B), but not in the cortex (data not shown), between the two experimental groups. Thus, hyperthyroid rats displayed accumulation of most of the lipids analyzed except for ceramides, which were reduced in the hypothalamus and increased in the cortex ([Figure S5](#mmc1){ref-type="supplementary-material"}C). Further analysis of individual ceramides showed that all species analyzed were decreased (Cer18, Cer20, and Cer24) or trended toward a decrease (Cer22) in the hypothalamus of hyperthyroid rats ([Figure 5](#fig5){ref-type="fig"}A). Consistent with this, we detected major changes in the mRNA expression profiles of key enzymes involved in the metabolism of complex lipids in the hypothalamus ([Figure 5](#fig5){ref-type="fig"}B), but not in the cortex ([Figure S5](#mmc1){ref-type="supplementary-material"}D), of hyperthyroid rats. Notably, the enzymes involved in ceramide metabolism were also affected by the hyperthyroid status in the hypothalamus, showing reduced expression of ceramide synthase (LASS1, also called CERS1, codified by *Lass1*, also called *Cers1*) and elevated expression of sphingomyelin synthase 1 (SGMS1, codified by *Sgms1*) ([Figure 5](#fig5){ref-type="fig"}B), which is consistent with the decreased ceramide concentration. Conversely, in the cortex of hyperthyroid rats there was significant upregulation of LASS1 ([Figure S5](#mmc1){ref-type="supplementary-material"}D), which agrees with the augmented ceramide levels.Figure 5Effect of THs and AMPK on Hypothalamic Ceramides or ER Stress(A--C) Ceramide levels (A), mRNA levels of the enzymes involved in the metabolism of complex lipids (B), and protein levels of the UPR in the hypothalamus of euthyroid or hyperthyroid rats (n = 8--15 rats/group) (C).(D) Protein levels of the UPR in the MBH of rats ICV treated with vehicle or T3 (n = 7 rats/group).(E and F) Protein levels of the UPR (E) and ceramide levels in the VMH of rats treated in the VMH with vehicle or T3 (n = 7--10 rats/group) (F).(G and H) Protein levels of the UPR (G) and ceramide levels in the VMH of rats treated in the VMH with GFP-expressing adenoviruses or adenoviruses encoding a AMPKα-DN (n = 7--9 rats/group) (H).(I) Protein levels of the UPR in the VMH of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or AMPKα-CA (n = 7 rats/group).(J) Protein levels of the UPR in the VMH of SF1-Cre AMPKα1^flox/flox^ (n = 7--14 rats/group).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus euthyroid, vehicle ICV, vehicle VMH, and GFP or hyperthyroid GFP versus hyperthyroid AMPKα-CA or SF1-Cre AMPKα1^flox/flox^ versus AMPKα1^flox/flox^. Data are expressed as mean ± SEM. The bands in gels from (C)--(E), (G), (I), and (J) have been spliced from the same original gels. See also [Figure S5](#mmc1){ref-type="supplementary-material"}.

THs Reduce Hypothalamic ER Stress {#sec2.9}
---------------------------------

Current evidence has demonstrated that central ceramide-induced lipotoxicity triggers endoplasmic reticulum (ER) stress, leading to weight gain and decreased sympathetic tone and BAT thermogenesis ([@bib10]). Thus, we speculated that the reduced hypothalamic ceramide concentration induced by THs might impact ER stress and the protein levels of the unfolded protein response (UPR). Our data showed that hyperthyroid rats have reduced protein levels of UPR markers in the hypothalamus, such as activating transcription factor 6 alpha (ATF6α), C/EBP homologous protein (CHOP), and phosphorylated PKR-like ER kinase (pPERK). Moreover, the protein levels of the chaperone GRP78 (glucose-regulated protein 78 KDa, which acts upstream of the UPR to modulate protein folding in reply to cellular insults that lead to ER stress) were increased in the hypothalamus of hyperthyroid rats ([Figure 5](#fig5){ref-type="fig"}C). Similarly, ICV administration of T3 promoted decreased levels of the entire UPR, together with increased GRP78, in the mediobasal hypothalamus (MBH) ([Figure 5](#fig5){ref-type="fig"}D). These responses were recapitulated when T3 was administered in the VMH ([Figure 5](#fig5){ref-type="fig"}E), which also decreased VMH ceramide concentration ([Figure 5](#fig5){ref-type="fig"}F). Overall, this evidence demonstrates that THs reduce hypothalamic ceramide content and ER stress. In contrast, according to the elevated ceramide levels, the UPR was upregulated in the cortex, which was indicative of induced ER stress ([Figure S5](#mmc1){ref-type="supplementary-material"}E). Next, we analyzed the UPR and the ceramide levels in the VMH of rats treated with adenoviruses harboring AMPKα-DN in that nucleus. We observed decreased ER stress ([Figure 5](#fig5){ref-type="fig"}G) and a tendency for a decrease in the VMH ceramide concentration ([Figure 5](#fig5){ref-type="fig"}H). Based on these observations, we hypothesized that the central effect of T3 on ER stress is mediated by specific inhibition of AMPK in the VMH. To address this possibility, adenoviruses encoding AMPKα-CA were injected into the VMH of hyperthyroid rats. Overexpression of AMPKα-CA reversed the hyperthyroid-induced downregulation of hypothalamic ER stress ([Figure 5](#fig5){ref-type="fig"}I). In keeping with this evidence, SF1-Cre AMPKα1^flox/flox^ mice showed decreased ER stress in the VMH ([Figure 5](#fig5){ref-type="fig"}J).

Ceramides and Induction of ER Stress Reverse the Effect of Central THs on BAT, but Not on Liver {#sec2.10}
-----------------------------------------------------------------------------------------------

To address whether decreased ceramide-induced lipotoxicity and ER stress might mediate the central actions of THs on liver and BAT metabolism, we ICV treated hyperthyroid rats with C6 ceramide. Central administration of ceramide induced a marked feeding-independent weight gain ([Figure 6](#fig6){ref-type="fig"}A), which was associated with increased ceramide levels (hyperthyroid vehicle, 100% ± 6.37%; hyperthyroid ceramide ICV, 148.45% ± 4.70%; p \< 0.001) and the UPR in the MBH ([Figure S6](#mmc1){ref-type="supplementary-material"}A) and, importantly, with decreased UCP1 protein levels ([Figure 6](#fig6){ref-type="fig"}B) and AMPK signaling ([Figure 6](#fig6){ref-type="fig"}C) in the BAT. These data demonstrate that central ceramide administration reversed the effect of central T3 on BAT metabolism. Of note, no changes were found when the AMPK pathway was assayed in the liver ([Figure 6](#fig6){ref-type="fig"}D), indicating that the effect on BAT function is specific. To control the effect of ceramide, we initially performed ICV administration of C6-dihydroceramide (C6-DHC, an inactive form, used as a negative control) to hyperthyroid rats. C6-DHC did not increase either body weight or food intake ([Figure S6](#mmc1){ref-type="supplementary-material"}B) or modulate BAT or hepatic metabolism ([Figures S6](#mmc1){ref-type="supplementary-material"}C--S6E) when compared with ceramide treatment. Finally, we treated hyperthyroid rats with adenoviruses overexpressing serine palmitoyltransferase long chain base subunit 1 and 2 (SPTLC1-2, a rate-limiting enzyme in ceramide synthesis pathway) into the VMH. As above, the specificity of the injections was verified by the expression of GFP in the VMH and the increased (2-fold) ceramide levels in that area after adenoviral treatment (GFP, 100% ± 13.2%; SPTLC1-2, 220.31% ± 79.88%; p \< 0.05). The findings recapitulate those we observed with central administration of ceramide: feeding-independent weight gain ([Figure S6](#mmc1){ref-type="supplementary-material"}F), increased ER stress in the VMH ([Figure S6](#mmc1){ref-type="supplementary-material"}G), and decreased AMPK activation and UCP1 expression in BAT ([Figures S6](#mmc1){ref-type="supplementary-material"}H and S6I), without affecting hepatic AMPK pathway ([Figure S6](#mmc1){ref-type="supplementary-material"}J).Figure 6Effect of Hypothalamic Ceramide-Induced Lipotoxicity and ER Stress on the Central Action of THs on Liver and BAT(A) Body weight change and food intake of hyperthyroid rats ICV treated with vehicle or C6 ceramide ICV (n = 9--10 rats/group).(B--D) Protein levels of UCP1 in the BAT (B) and the AMPK pathway in the BAT (C) and liver (D) of hyperthyroid rats ICV treated with vehicle or C6 ceramide ICV (n = 7 rats/group).(E) Body weight change and food intake of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or GRP78-DN (n = 22--25 rats/group).(F--H) Protein levels of UCP1 in the BAT and the AMPK pathway in the BAT and liver of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or GRP78-DN (n = 13--15 rats/group).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus hyperthyroid vehicle ICV or hyperthyroid GFP VMH. Data are expressed as mean ± SEM. The bands in gels from (C), (F), and (G) have been spliced from the same original gels. See also [Figure S6](#mmc1){ref-type="supplementary-material"}.

To assess the role of ER stress, we targeted GRP78 using an adenoviral vector encoding a dominant-negative isoform (GRP78-DN), which was injected into the VMH. Administration of GRP78-DN adenovirus into the VMH of hyperthyroid rats promoted feeding-independent weight gain ([Figure 6](#fig6){ref-type="fig"}E) associated with increased ER stress in the VMH ([Figure S6](#mmc1){ref-type="supplementary-material"}K), reduced UCP1 levels ([Figure 6](#fig6){ref-type="fig"}F), and AMPK signaling in BAT ([Figure 6](#fig6){ref-type="fig"}G). No changes were detected in hepatic AMPK signaling ([Figure 6](#fig6){ref-type="fig"}H). Altogether, this evidence suggests that ceramide levels and ER stress in the VMH mediate the actions of T3 and AMPK on BAT, but not on liver metabolism.

JNK Inhibition Reverses the Central Actions of T3 on Liver, but Not on BAT {#sec2.11}
--------------------------------------------------------------------------

Recent evidence has shown that hypothalamic protein kinase C (PKC) plays a major role in the regulation of hepatic glucose metabolism through the ANS ([@bib3]). We found that PKCδ, but not PKCε, protein levels were elevated in the hypothalamus or the MBH of hyperthyroid and ICV T3-treated rats, respectively ([Figures S7](#mmc1){ref-type="supplementary-material"}A and S7B), indicative of a potential role of PKCδ in T3 action. To examine this further, we used the PKC inhibitor rottlerin that, when given centrally, decreased protein levels of PKCδ and its downstream target, phosphorylated extracellular-signal-regulated kinase (pERK) ([Figure S7](#mmc1){ref-type="supplementary-material"}C). However, our data showed no impact of rottlerin on hepatic pAMPK and pACC protein levels either in hyperthyroid or ICV T3-treated rats ([Figures S7](#mmc1){ref-type="supplementary-material"}D and S7E), indicating that PKC pathway was not involved in the central actions of THs on liver.

c-Jun N-terminal kinase 1 (JNK1) plays a crucial role in the hypothalamic regulation of feeding and glucose metabolism ([@bib43], [@bib56], [@bib53]). We analyzed JNK protein levels in the hypothalamus of hyperthyroid, ICV T3-treated, and VMH T3-treated rats. Interestingly, the protein levels of phosphorylated JNK (pJNK) were increased in the hypothalamus, MBH, and VMH, respectively, of those models ([Figures 7](#fig7){ref-type="fig"}A--7C). Furthermore, the effect of hyperthyroidism and T3 on pJNK was reversed when rats were simultaneously treated with AMPKα-CA into the VMH, indicating that the effect of THs was mediated by AMPK, which is upstream of JNK ([Figures 7](#fig7){ref-type="fig"}D and 7E). SF1-Cre AMPKα1^flox/flox^ mice showed increased pJNK protein levels in the VMH, therefore recapitulating the effects of THs ([Figure 7](#fig7){ref-type="fig"}F).Figure 7Effect of JNK1 in the VMH on the Central Actions of T3 on Liver and BAT(A) Protein levels of JNK and pJNK in the hypothalamus of euthyroid and hyperthyroid rats (n = 7 rats/group).(B) Protein levels of JNK and pJNK in the MBH of rats ICV treated with vehicle or T3 (n = 7 rats/group).(C) Protein levels of JNK and pJNK in the VMH of rats treated in the VMH with vehicle or T3 (n = 7 rats/group).(D) Protein levels of JNK and pJNK in the VMH of hyperthyroid rats treated in the VMH with adenoviruses encoding GFP or AMPKα-CA (n = 7 rats/group).(E) Protein levels of JNK and pJNK in the VMH of rats ICV treated with vehicle or T3 and treated in the VMH with adenoviruses encoding GFP or AMPKα-CA (n = 11 rats/group).(F) Protein levels of JNK and pJNK in the VMH of SF1-Cre AMPKα1^flox/flox^ mice (n = 7 mice/group).(G) Body weight change and food intake of wild-type (WT) and JNK1 KO mice ICV treated with vehicle or T3 (n = 12--16 mice/group).(H and I) Protein levels of the AMPK pathway in the liver of WT (H) or JNK1 KO mice (I) ICV treated with vehicle or T3 (n = 12--16 mice/group).(J and K) Oil Red O (40×; scale bar, 50 μm) staining analysis (J) and TG levels in the liver of WT or JNK1 KO mice ICV treated with vehicle or T3 (n = 11--15 mice/group) (K).(L) Body weight change and food intake of JNK2 KO-JNK1^flox/flox^ mice ICV treated with vehicle or T3 and treated in the VMH with AAV expressing GFP or Cre (n = 9-12 mice/group).(M and N) Protein levels of the AMPK pathway in the liver of JNK2 KO-JNK1 floxed mice ICV treated with vehicle or T3 and treated in the VMH with AAV expressing GFP (M) or Cre (N) (n = 9--12 mice/group).(O and P) Oil Red O (40×; scale bar, 50 μm) staining analysis (O) and TG levels in the liver of JNK2 KO-JNK1^flox/flox^ mice ICV treated with vehicle or T3 and treated in the VMH with AAV expressing GFP or Cre (n = 6--12 mice/group) (P).^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001 versus euthyroid, vehicle ICV, vehicle VMH, GFP VMH, and T3 ICV vehicle ICV. Data are expressed as mean ± SEM. The bands in gels from (A)--(F), (H), (I), (M), and (N) have been spliced from the same original gels. See also [Figure S7](#mmc1){ref-type="supplementary-material"}.

We also tested whether JNK might mediate the central actions of T3 on liver lipogenesis using the JNK inhibitor SP600125 ([@bib21]). When given centrally, SP600125 decreased the MBH levels of phosphorylated c-Jun (p-c-Jun) and signal transducer and activator of transcription 3 (pSTAT3), indicating functional inhibition of JNK ([Figure S7](#mmc1){ref-type="supplementary-material"}F). Of note, SP600125 did not interfere with the central effect of T3 on pAMPK in the MBH ([Figure S7](#mmc1){ref-type="supplementary-material"}G), confirming that JNK was not upstream of AMPK. In addition, SP600125 treatment did not revert the central actions of T3 on either BAT UCP1 or AMPK pathway protein levels ([Figures S7](#mmc1){ref-type="supplementary-material"}H and S7I). However, SP600125 was also able to reverse the central actions of T3 on the hepatic AMPK pathway, as indicated by the increased pAMPK and pACC protein levels ([Figure S7](#mmc1){ref-type="supplementary-material"}J), alongside a reduction in lipid and TG content ([Figures S7](#mmc1){ref-type="supplementary-material"}K and S7L), indicating that the effect was liver specific.

JNK1 in the VMH Mediates the Central Actions of T3 on Liver, but Not on BAT {#sec2.12}
---------------------------------------------------------------------------

Central T3 elicited feeding-independent weight loss in both wild-type (WT) and *jnk1* null (JNK1 KO) mice ([Figure 7](#fig7){ref-type="fig"}G) and decreased AMPK signaling in the liver of WT mice ([Figure 7](#fig7){ref-type="fig"}H), but not in JNK1 KO mice ([Figure 7](#fig7){ref-type="fig"}I). In line with this, hepatic lipid and TG content ([Figures 7](#fig7){ref-type="fig"}J and 7K) was elevated in WT, but not in JNK1 KO mice. Notably, AMPK signaling was decreased in the ventromedial hypothalamus of both WT and JNK1 KO ([Figure S7](#mmc1){ref-type="supplementary-material"}M), consistent with the observation above that AMPK is upstream of JNK1. UCP1 protein levels in BAT were increased by T3 in both WT and JNK1 KO mice ([Figure S7](#mmc1){ref-type="supplementary-material"}N), suggesting that JNK1 mediated the actions of THs on liver, but not on BAT function.

We repeated the experiment using global *jnk2* null (JNK2 KO) mice, which also carry floxed alleles of the *jnk1* gene. We treated these mice in the VMH with adeno-associated viruses (AAVs) expressing GFP or the Cre-recombinase before ICV administration of T3, meaning that a group of *jnk2* null mice have normal *jnk1* and the ones treated with the Cre-recombinase have VMH-specific deletion of *jnk1* gene. The infection efficiency was demonstrated by decreased levels of p-c-Jun and pSTAT3 in the VMH of Cre-treated mice, indicating functional inhibition of JNK1 ([Figure S7](#mmc1){ref-type="supplementary-material"}O). ICV T3 decreased body weight in a feeding-independent manner in both groups ([Figure 7](#fig7){ref-type="fig"}L) and the AMPK signaling pathway in the liver of JNK2 KO-JNK1^flox/flox^ mice that received AAV-expressing GFP ([Figure 7](#fig7){ref-type="fig"}M). However, the effect of central T3 on liver was totally absent in the mice previously treated with AAV-Cre in the VMH ([Figure 7](#fig7){ref-type="fig"}N). Accordingly, T3 increased lipid and TG content ([Figures 7](#fig7){ref-type="fig"}O and 7P) in the liver of GFP-, but not Cre-treated, mice. Consistent with our findings in the JNK1 KO mice, T3 decreased pAMPK levels in the VMH of both models ([Figure S7](#mmc1){ref-type="supplementary-material"}P) and increased UCP1 protein levels in BAT ([Figure S7](#mmc1){ref-type="supplementary-material"}Q). Overall, these data indicate that JNK1 in the VMH mediates the central T3 actions on hepatic lipogenesis, but not BAT function.

Discussion {#sec3}
==========

THs regulate lipid synthesis in liver, muscle, WAT, BAT, and hypothalamus by modulating expression and activation of key lipogenic enzymes such as ACC, FAS, and AMPK ([@bib29], [@bib37]), as well as autophagy ([@bib50]). Although relevant effects of THs on energy balance have been reported, the central action of THs on peripheral lipid metabolism remains uncertain. This question is of interest for several reasons. First of all, very recent evidence shifted the "classical" view of the mode of action from "peripheral perspective" ([@bib49]) to a "central perspective" ([@bib16], [@bib58], [@bib29]), recognizing the brain as a major mediator of the metabolic actions of THs. Second, dysregulation of the thyroid axis in humans leads to marked alterations in energy balance; for example, up to 85% of patients with hyperthyroidism exhibit weight loss despite increased food intake ([@bib49], [@bib29]). Moreover, hyperthyroid patients show increased hepatic lipogenesis ([@bib6]), enhanced lipolysis, and TG and FA cycling, which contribute to higher EE ([@bib4]). Third, the potential of THs as a target in the treatment of obesity has been known for decades and recent evidence has placed glucagon-T3 conjugates in the possible pipeline for obesity treatment ([@bib15]). Thus, the precise understanding of the central actions of T3 on metabolism is necessary for the development of therapies for obesity, but also for TH-associated metabolic disorders.

We focused on the contribution of the central effects of THs to the lipid alterations observed in the hyperthyroid state. Our data showed that, when administered centrally, T3 promotes the same pattern of expression in pro-lipogenic enzymes as observed in the hyperthyroid liver and BAT. Notably, these actions specifically target the VMH. Indeed, administration of the hormone into the ARC did not recapitulate the effects on liver and BAT lipogenic programs evoked by VMH T3. Recent evidence has substantially expanded our understanding of the metabolic roles of the VMH, demonstrating extensive functionality of this hypothalamic area in the control of food intake ([@bib12]), EE ([@bib28], [@bib60], [@bib31], [@bib10]), and peripheral glucose homeostasis ([@bib52]). Of note, many of those effects also appear to involve one specific neuronal population of the VMH, namely SF1 neurons, the same population where AMPK conducts its actions on BAT and liver metabolism. This is based on our finding that SF1 neuron-specific ablation of the AMPKα1 isoform, which is downregulated by THs ([@bib28]), entirely recapitulates the central effects of T3 on energy balance. Altogether, this evidence demonstrates that SF1 neurons of the VMH mediate the central effect of THs on metabolism. Although nearly all VMH neurons express SF1, numerous subpopulations can be distinguished based on their differential expression of several proteins, including brain-derived neurotrophic factor ([@bib47]), insulin and leptin receptors ([@bib26], [@bib12]), estrogen receptor α ([@bib60]), and vesicular glutamate transporter 2 (VGLUT2) ([@bib52], [@bib8]). Besides that, SF1 neurons project broadly within the CNS. They send axons to the C1 catecholamine cell group of the rostral ventrolateral medulla (RVLM), which controls the sympathetic outflow to BAT ([@bib27], [@bib36]). Neuronal fibers originating from the VMH SF1 neurons also reach other hypothalamic regions involved in SNS and PSNS outflow, including the ARC and PVH ([@bib27], [@bib36]). Notably, specific ablation of VGLUT2 in SF1 neurons has been shown to impair neuronal activation in the DMV ([@bib52]), a key site that gives rise to the PSNS fibers innervating the liver ([@bib16]). That heterogeneity could explain the ability of these neurons to control both the SNS and the PSNS, although it is likely that the neuronal circuits modulating both branches of the ANS may involve separate subpopulations of SF1 neurons.

We have also defined the exact downstream mechanisms linking AMPK in the VMH with peripheral metabolism. We provide evidence that a T3-induced decrease in AMPK in the VMH promotes a dichotomic mechanism involving ceramide-ER stress and JNK1 to modulate BAT and liver function, respectively. Recent data have shown that ceramide-induced lipotoxicity and ER stress lead to decreased thermogenesis and weight gain ([@bib10]). Our data show that a T3-induced reduction in AMPK activity promotes decreased hypothalamic ceramide concentration and subsequent reduction in ER stress. Of note, augmented ceramide levels in the cortex lead to increased ER stress at this level, which suggests that THs induce regional modulation of lipid metabolism and ER stress in the brain. The mechanistic role of ceramides on the hyperthyroid phenotype was demonstrated by administration of C6 ceramide, overexpression of SPTCL1-2 in the VMH, and a specific increase of ER stress in the VMH by GRP78-DN, all of which blocked TH actions on BAT, but not on liver. Overall, these data suggest that AMPK-induced changes in ceramides and ER stress, specifically in the VMH, mediate the central actions of THs on BAT and energy balance. Although the precise mechanism whereby T3 regulates AMPK signaling is yet to be elucidated, our previous findings have clearly demonstrated that this effect is mediated by TRα1 ([@bib28]). Considering the rapid time course of TH effects we report, it is tempting to speculate that non-genomic actions through the membrane-bound TRα ([@bib24]) or the mitochondrial TRα isoform p43 ([@bib44]) could contribute to the regulation of AMPK. However, using a transgene mouse for a GFP-tagged TRα, it has been demonstrated that at least in the brain all T3-binding isoforms from this receptor are nuclear ([@bib57]). Consequently, since our observations are still within the timeframe of T3-mediated genomic actions, which can be observed as early as 1--3 hr *in vivo* ([@bib22], [@bib14]), it seems most likely that T3 modulates AMPK signaling through TRα1-mediated changes in gene transcription, a possibility that is further supported by the decreased AMPKα1 (total, non-phosphorylated) protein levels in the hypothalamus after T3 and T4 treatments ([@bib28]). Another important question is how modulation of ER stress and ceramides could be connected to changes in neuronal activity. It has been reported that ER stress causes altered calcium signaling in neurons by impairing the activity of ER-resident calcium-release channels and inositol 1,4,5-trisphosphate receptor (IP~3~R); notably, GRP78 (which is increased in the hypothalamus after THs treatments) plays a protective role ([@bib39], [@bib19]). The interaction of ER and mitochondria, which modulates neuronal excitability, is another potential mechanism. For example, ablation of mitofusin 2 (MFN2), which results in loss of ER-mitochondria contacts, increases ER stress and decreases neuronal firing ([@bib13], [@bib46]). Whether central T3 impacts the ER-mitochondria connection in hypothalamic neurons is presently unknown, but further work is warranted.

We present conclusive evidence that T3 regulates hepatic lipogenic pathway by modulating AMPK and JNK1, specifically in the VMH, leading to hepatic vagal activation, as supported by VGX experiments. The positive effect of JNK1 on neuronal activation has been previously described in AgRP neurons ([@bib53]). The molecular mechanisms underlying this action are unclear, but it is known that JNK1 regulates several processes related to brain morphogenesis, neuronal activity, axo-dendritic architecture, and synaptic plasticity ([@bib48], [@bib59], [@bib34]). The net result of central T3 is a PSNS-mediated increase of the lipogenic rate in the liver. In this regard, our data demonstrate that de novo FA synthesis and uptake into liver are increased and incorporated into TGs. The concomitant increase in the appearance of ^14^C in BAT is consistent with the data showing that central (ICV or VMH) T3 increases the thermogenic program in this tissue, the glucose uptake, and the mitochondrial activity and dynamics, leading to increased EE and decreased RQ. Since THs modulate FA uptake in a tissue-specific manner ([@bib25]), it is likely that the ^14^C in BAT arises from both direct uptake of circulating FA ([@bib41]) and hepatic TG in the form of TG-rich lipoproteins (TRLs) that are known to contribute greatly to BAT lipid content during thermogenesis ([@bib2]). Therefore, T3 acts within the VMH in a manner that seems to maximize the metabolic capacities of each organ, leading to an overall effect of negative energy balance and weight loss, despite unchanged food intake.

In summary, central T3 regulates hepatic metabolism through the vagus nerve and BAT through the SNS, leading to increased lipid oxidation and thermogenesis. This physiological pathway is mediated by AMPK (specifically in SF1 neurons of the VMH), which also exerts a dichotomic action on ceramide-induced ER stress and JNK1. Overall, our results uncover the interconnected nature of these mechanisms in terms of TH actions at the whole-body level to regulate organism lipid handling and their relevance to energy and metabolic homeostasis. This knowledge should aid in the more rationally based design of drugs for the treatment of obesity and its comorbidities.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------
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Contact for Reagent and Resource Sharing {#sec4.2}
----------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Miguel López (<m.lopez@usc.es>).

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

### Animals {#sec4.3.1}

Adult male Sprague-Dawley rats (8-10 weeks old, 200-250 g; Animalario General USC, Santiago de Compostela, Spain), adult male null *Jnk1* mice (C57BL/6 background; 8-10 weeks old), adult male null *Jnk2* and *Jnk1*^flox/flox^ and their wild-type mice (C57BL/6 background; 8-10 weeks old; Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III, Madrid, Spain), and adult male null SF1-Cre AMPKα1^flox/flox^ mice (mixed background; 20 weeks old; The Jackson Laboratory, Bar Harbor, ME, USA) and their littermates were used. During all experimental approaches the animals were daily monitored for food intake and body weight changes, at the same hour. Protocols used for animals that received radiolabeled lipid were in accordance with the United Kingdom Home Office legislation (Animal Scientific Procedure Act 1986). All the other experiments were performed in agreement with the International Law on Animal Experimentation and were approved by the USC Ethical Committee (Project ID 15010/14/006) and University of Iowa Institutional Animal Care and Use Committee.

To generate SF1 neuron-specific AMPKα1 knock-out mice (SF1-Cre AMPKα1^flox/flox^), SF1-Cre mice *(Tg(Nr5a1-cre)Lowl/J*, stock number 012462; The Jackson Laboratory, Bar Harbor, ME, USA) were crossed with AMPKα1 floxed mice (AMPKα1^flox/flox^ mice, *Prkaa1tm1.1Sjm/J*; stock number 014141; The Jackson Laboratory; Bar Harbor, ME, USA) that possess loxP sites flanking exon 3 of *Prkaa1* gene. Littermates of the same mixed background strain generation were used as controls. Animals were genotyped by PCR with the following set of primers: AMPKα1 loxP site: Forward: 5′-CCCACCATCACTCCATCTCT-3′, Reverse: 5′-AGCCTGCTTGGCACACTTAT-3′; AMPKα1 deleted allele: Forward: 5′-CCCACCATCACTCCATCTCT-3′, Reverse: 5′-CCCACATAGGAAAGCGTGTT-3′ and SF1-Cre transgene: Forward: 5′-CTGAGCTGCAGCGCAGGGACAT-3′, Reverse: 5′-TGCGAACCTCATCACTCGTTGCAT-3′. The deleted allele produced an amplicon of 530 bp.

### Housing conditions {#sec4.3.2}

The animals were housed with an artificial 12 hr light (8:00 to 20:00)/12 hr dark cycle, under controlled temperature and humidity conditions and allowed to free access to standard laboratory chow and tap water. For all the procedures, the animals (rats and mice) were caged individually, unless otherwise stated, and used for experimentation 5-7 days later. During this post-operative recovery period the animals became accustomed to the handling procedure under non-stressful conditions. SF1-Cre AMPKα1^flox/flox^ mice and their littermates were housed in groups, except for food intake analyses, calorimetric system and the β3-AR antagonist experiment, for which they were caged individually. During the induction of hyperthyroidism and VGX recovery time the rats were housed in groups (4 rats/cage).

Method Details {#sec4.4}
--------------

### Induction of hyperthyroidism {#sec4.4.1}

Hyperthyroidism was induced by chronic subcutaneous (s.c.) administration of L-thyroxine (T4, 100 μg/day, dissolved in 200 μL of saline; Sigma-Aldrich; St Louis, MO, USA) for a period of three weeks (21 days), as previously described ([@bib28], [@bib54], [@bib32]). Euthyroid (control) rats were treated with vehicle (saline).

### Intracerebroventricular treatments {#sec4.4.2}

Intracerebroventricular (ICV) cannulae were stereotaxically implanted under ketamine/xylazine anesthesia or a mix of inhaled isoflurane and oxygen, as previously described using the following coordinates 1.6 mm lateral to bregma, 0.6 mm posterior, 4.5 mm deep ([@bib28], [@bib54], [@bib31], [@bib10]). For the chronic experiments, rats and mice received either a single ICV daily administration of triiodothyronine (T3; for rats 4 ng/day, during 5 days, dissolved in 5 μL of saline; for mice 8 ng/day, during 5 days, dissolved in 1 μL of saline; Sigma-Aldrich; St Louis, MO, USA) at 20:00, just before turning the light off ([@bib28], [@bib54], [@bib32]). For the acute SNA recording, c-FOS analyses in the DMV and ^14^C-oleate experiments rats received the same single dose of T3 or 1:50 saline:DMSO during 3 hr. The JNK inhibitor SP600125 (Tocris Bioscience; Bristol, UK) was given ICV (0.5 μg/μl/day, dissolved in 15:50 saline:DMSO) ([@bib21]) during 7 days using osmotic minipump flow moderator (Model 2001; Alzet Osmotic Pumps, Cupertino, CA, USA). The PKC inhibitor, rottlerin (Calbiochem; Billerica, USA) was given ICV (60 μmol/L, dissolved in saline) ([@bib5]) for 7 days using osmotic minipump flow moderator (Model 2001; Alzet Osmotic Pumps, Cupertino, CA, USA). The C6 ceramide (N-Hexanoyl-D-sphingosine) and the C6-DHC (C6-dihydroceramide) were given ICV (1.25 mg/ml dissolved in saline containing 1/3 of DMSO; Sigma-Aldrich; St Louis, MO, USA) or vehicle (saline containing 1/3 of DMSO; control rats) for 7 days using osmotic minipump flow moderator (Model 2001; Alzet Osmotic Pumps, Cupertino, CA, USA) ([@bib21], [@bib10]).

### ^14^C-oleate infusions {#sec4.4.3}

Rats equipped with ICV cannulae were given 7 days to recover before infusions. Rats anesthetized with α-chloralose (2.5% solution, 50 mg/kg; MP Biomedical; Solon, OH, USA) were placed on heating pads before a catheter is inserted into the femoral vein. Anesthesia was infused (25 mg/kg/hr) alongside the ^14^C-oleate tracer (3000 Bq/min, total dose 0.6 MBq in 0.3 μmol of oleate; ^14^C labeled 2-Deoxy-Glucose (Deoxy-D-glucose, 2-\[14C(U)\]; Perkin Elmer, Waltham, MA, USA) ([@bib25]). After 30 min baseline, serum measurements were taken and rats dosed with vehicle (DMSO) or T3 (4 ng for 3 hr, dissolved in 5 μL of DMSO; Sigma-Aldrich, St Louis, MO, USA) via ICV cannulae. Blood samples were taken at regular intervals until the experiment was terminated by sacrificing the animals and collecting tissues.

### Stereotaxic microinjection of T3 and viral vectors {#sec4.4.4}

Animals were placed in a stereotaxic frame (David Kopf Instruments; Tujunga, CA, USA) under ketamine/xylazine anesthesia. The ARC and the VMH were targeted bilaterally using a 25-gauge needle (Hamilton; Reno, NV, USA). The injections were directed to the following stereotaxic coordinates: a) for the VMH of rats: 2.8 mm and 3.2 mm posterior to the bregma, ± 0.6 mm lateral to midline and 10.1 mm deep; b) for the VMH of mice: 1.7 mm posterior to the bregma, ± 0.5 mm lateral to midline and 5.5 mm deep c) for the ARC of rats 2.8 mm posterior, ± 0.3 mm lateral to bregma and 10.2 mm deep. For acute treatments, T3 (Sigma-Aldrich, St Louis, MO, USA; 16 ng in 1 μL of 1:50 saline:DMSO; during 12 hr) or vehicle (100 nL of 1:50 saline:DMSO) were given. For chronic nuclei-specific treatments, T3 was given at 4 ng/day (in saline + 1 mM NaOH) and vehicle (saline + 1 mM NaOH) used as control. The selection of these doses was based on previous reports ([@bib28], [@bib54], [@bib32]). Nuclei-specific injections were delivered via a permanent 28-gauge stainless steel cannula (Plastics One, Roanoke, VA, USA) inserted bilaterally either in the VMH or ARC. A catheter tube was connected from each infusion cannula to an osmotic minipump flow moderator (Model 1007D; Alzet Osmotic Pumps, Cupertino, CA, USA). These pumps had a flow rate of 0.5 μL/hour during 7 or 28 days of treatment. The osmotic minipumps were inserted in a subcutaneous pocket on the dorsal surface created using blunt dissection and the treatment was given for 7 or 28 days ([@bib21], [@bib10]).

Adenoviral (GFP, AMPKα-DN, AMPKα-CA, GRP78-DN, TR-DN and SPTLC1-2; Viraquest; North Liberty, IA, USA and SignaGen; Rockville, MD, USA) or adeno-associated (Cre; SignaGen; Rockville, MD, USA) vectors were delivered in the VMH of rats or mice using the aforementioned coordinates at a rate of 200 nl/min for 5 min for rat and 10 min for mouse (1 μl/injection site) as previously reported ([@bib28], [@bib54], [@bib31], [@bib10]). Animals were treated for 5-7 days (adenovirus) or 30 days (Cre).

### Peripheral treatments {#sec4.4.5}

To test whether T3 ICV leaked to the periphery, T3 (Sigma-Aldrich; St Louis, MO, USA) was given intraperitoneally (IP; 4 ng/day, dissolved in 200 μL of 1:50 saline:DMSO) during 4 days ([@bib28]). The adrenergic receptor beta 3 (β3-AR) specific antagonist SR59230A (\[3-(2-ethylphenoxy)-1-\[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino\]-2S-2-propanol-oxalate\]; 3 mg/Kg/day dissolved in saline:DMSO, 1:50 saline:DMSO; Tocris Bioscience; Bristol, UK) ([@bib28], [@bib31]) was administrated subcutaneously (s.c.) and animals were treated during 2 days before the T3 injections for rats and 7 days for SF1-Cre AMPKα1^flox/flox^ mice.

### Vagotomy {#sec4.4.6}

To investigate the impact of the vagus nerve on T3 effects on hepatic metabolism, sham control and VGX rats were infused ICV or VMH with T3 at the doses previously described. The vagotomy surgical procedure was performed as previously described ([@bib21]). Briefly, under ketamine--xylazine anesthesia rats were placed on their backs and a midline abdominal incision was made. The liver was then carefully moved to the right exposing the esophagus. Dorsal and ventral branches of the vagus nerve were exposed and dissected from the esophagus. Each branch of the nerve was ligated with surgical suture at two points as distally as possible to prevent bleeding, and then cauterized between the sutures. The abdominal muscles and the skin were then sutured with surgical silk. Sham surgeries were also performed, in which each trunk of the nerve was exposed but not tied or cauterized. The animals were allowed to recover for 15 days before other procedures. The effectiveness of the vagotomy was assessed at the end of the study by post-mortem analysis of the stomach. Only the rats that showed an evident increase in stomach size after vagotomy (due to motoric dysfunction) were included in the analysis ([@bib21]).

### Positron emission tomography--computed tomography {#sec4.4.7}

#### Chemicals {#sec4.4.7.1}

2-^18^F-Fluoro-2-Deoxy-2-Glucose (^18^F-FDG) was produced on a TRACERlab MX synthesizer (GE Healthcare; Little Chalfont, UK), cassettes and reagent kits were from ABX (Advanced Biochemical Compounds, Radeberg, Germany) with the standard method supplied from GE (nucleophilic substitution). The final product had a radiochemical purity more than 95% with a specific activity closely of 1000 Mbq/ml and the osmolality was around 200-300 mOsm/kg.

#### PET imaging system {#sec4.4.7.2}

Whole-body microPET/CT images were acquired with the Albira PET/CT Preclinical Imaging System (Bruker Biospin; Woodbridge, CT, US). The PET subsystem comprises three rings of eight compact modules based on monolithic crystals coupled to multi-anode photomultiplier tubes (MAPMTs), which form an octagon with an axial FOV of 40 mm/ring and a transaxial FOV of 80 mm in diameter. The PET radial spatial resolution is 1.55 mm (full width at half-maximum) and the absolute sensitivity of the system is 2% for a 350-650 keV energy window and a 5 ns timing window.

#### Image acquisition {#sec4.4.7.3}

Rats were anesthetized with a gaseous mixture of 2.5% isoflurane in oxygen in an anesthesia chamber before the injection of (7.4 ± 1.85) MBq of ^18^F-FDG on the tail vein. The anesthesia was interrupted immediately after the injection and the rats were placed back on the cage and remained awake during the uptake period. The acquisition was performed 45 ± 10 min after the ^18^F-FDG injections. Again, animals were pre-anesthetized with 2.5% isoflurane in oxygen in an anesthesia chamber, approximately during two minutes, and then transported to the scanner bed, where they were kept asleep under a concentration of 2% isoflurane in oxygen. Two bed positions were acquired during 30 min for scanning the whole-body of the animal. Images were generated by using the Bruker Albira Suite Software Version 5.0. Scatter and random coincidences were corrected by using the algorithms provided by the manufacturer. Attenuation correction was not performed. Images were reconstructed by using the maximum likelihood expectation maximization (MLEM) algorithm: 6 iterations were performed with an output pixel size of 0.4 × 0.4 × 0.4 mm^3^.

#### Image analysis and statistics {#sec4.4.7.4}

The brown fat area was delineated by using image tools implemented the AMIDE Software (<http://amide.sourceforge.net/>) to generate a three-dimensional spherical volume of interest with radius of 6 mm and centered on the brown fat area. Thus, mean standardized uptake values (SUV) were calculated. The PET-CT analysis was performed in the Molecular Imaging Unit of the Department of Nuclear Medicine of University of Santiago de Compostela.

### Calorimetric system and nuclear magnetic resonance {#sec4.4.8}

Animals were analyzed for EE, RQ and LA using a calorimetric system (LabMaster; TSE Systems; Bad Homburg, Germany). Animals were placed in a temperature-controlled (24°C) box through which air was pumped. After calibrating the system with the reference gases (20.9% O~2~, 0.05% CO~2~ and 79.05% N~2~), the metabolic rate was measured for 2-3 days, as previously shown ([@bib21], [@bib31]). EE, RQ (VCO~2/~VO~2~) and LA were recorded every 30 min. Animals were placed for adaptation for 1 week before starting the measurements.

For the measurement of body composition, we used nuclear magnetic resonance (NMR) (Whole Body Composition Analyzer; EchoMRI; Houston, TX). EchoMRI is a body composition analyzer for live subjects measuring body fat and lean masses with short scan times to keep the comfort of the animals. Animals do not need to be anesthetized neither other special preparation before measurement. They are placed in a holder of custom-defined size during the measurement (measuring time: 0.5-3.2 min). Two measurements were done for animal, as previously shown ([@bib21], [@bib31]).

### BAT Temperature measurements {#sec4.4.9}

Skin temperature surrounding BAT was recorded with an infrared camera (B335: Compact-Infrared-Thermal-Imaging-Camera; FLIR; West Malling, Kent, UK) and analyzed with a specific software package (FLIR-Tools-Software, FLIR; West Malling, Kent, UK) as previously shown ([@bib31], [@bib10]). For each image, the area surrounding BAT was delimited and the average temperature of the skin area was calculated as the average of 2 pictures/animal.

### Sympathetic nerve activity recording {#sec4.4.10}

Multi-fiber recording of sympathetic nerve activity (SNA) was obtained from the nerve subserving BAT as previously described ([@bib28], [@bib31], [@bib10]). Animals were anesthetized using intraperitoneal ketamine (91 mg/kg) and xylazine (9.1 mg/kg) and maintained anesthesia with α-chloralose (initial dose: 25 mg/kg, sustain dose: 50 mg/kg/h) via a catheter inserted in the femoral vein. The trachea was cannulated, and each rat was allowed to breathe spontaneously oxygen-enriched air. Rectal temperature was maintained at 37.5°C using a temperature-controlled surgical table and a lamp. We obtained multi-fiber recording of SNA from the nerve subserving BAT. Using a dissecting microscope, a nerve fiber innervating interscapular BAT was identified, placed on the bipolar platinum-iridium electrode. Each electrode was attached to a high-impedance probe (HIP-511, Grass Instruments, Warwick, RI, USA) and the nerve signal was amplified 10^5^ times with a Grass P5 AC pre-amplifier (Grass Instruments, Warwick, RI, USA). After amplification, the nerve signal was filtered at a 100- and 1000-Hz cutoff with a nerve traffic analysis system (Model 706C, University of Iowa Bioengineering; Iowa City, IA, USA). The nerve signal was then routed to an oscilloscope (Model 54501A, Hewlett-Packard; Palo Alto, CA, USA) for monitoring the quality of the sympathetic nerve recording and to a resetting voltage integrator (Model B600c, University of Iowa Bioengineering, Iowa City, IA, USA). BAT SNA measurements were made every 15 min during 6 hr for the T3 ICV treatment in rats. For the analysis of SNA in SF1-Cre AMPKα1^flox/flox^ mice and their control littermates, basal measurements were performed during 30 min. To ensure that electrical noise was excluded in the assessment of sympathetic outflow, we corrected each SNA recording for post-mortem background activity.

### Sample processing {#sec4.4.11}

Rats and mice were killed by cervical dislocation. From each animal, either the whole brain (for IHC), the hypothalamus, or the MBH, VMH and ARC (dissected from the whole hypothalamus), as well as the liver and the BAT (for western blot or RT-PCR) were harvested and immediately homogenized on ice to preserve phosphorylated protein levels. Samples were stored at −80°C until further processing. Dissection of the VMH and ARC was performed by micropunches under the microscope ([@bib28], [@bib31], [@bib10], [@bib32]). The specificity of the VMH dissections was confirmed by analyzing the mRNA of steroidogenic factor 1 (SF1) and proopiomelanocortin (POMC) (data not shown).

### Quantification of lipids {#sec4.4.12}

Tissues (30 mg) were homogenized with 10 volumes of ice-cold phosphate buffered saline (PBS) in a Potter homogenizer (20 strokes). Fatty acids were measured in homogenates using a kit (Wako Chemicals; Richmond, VA; US) and TG were quantified as described ([@bib33]). Briefly, lipids were extracted from 1.5 mg of protein from homogenates ([@bib17]) and TG were measured in the lipid extract with a kit (A. Menarini Diagnostics; Ripolli, Italy).

### De novo lipogenesis in tissues {#sec4.4.13}

De novo lipogenesis was performed as previously described ([@bib40]) with slight modifications ([@bib1]). Freshly isolated tissue slices (40 mg) were incubated in high glucose Dulbecco's Modified Eagle Medium (DMEM) with insulin (150 nM) and 20 μM acetate with \[^3^H\] acetic acid 20 μCi/ml for 4 hr. Tissue slices were washed five times in cold PBS, homogenated in PBS and lipids were extracted as previously described ([@bib17]). Then, lipids were separated by thin-layer chromatography (TLC) ([@bib42]), the band corresponding to TG was scraped and the radioactivity was measured in a scintillation counter.

### Fatty acid oxidation in tissues {#sec4.4.14}

Beta oxidation was assessed as described before ([@bib20], [@bib18]). Fresh liver and BAT pieces were homogenated in a Potter homogenizer (5 strokes) in cold buffer (25 mM Tris-HCl, 500 nM sucrose, 1 mM EDTA-Na~2~ pH 7,4) and sonicated for 10 s. Then, the homogenates were centrifuged at 500 xg for 10 min at 4°C. Approximately 500 μg of protein from the homogenates supernatant was used for the assay in a volume of 200 μl. The reaction started by adding 400 μl of assay mixture containing 200 μM of 0.5 μCi/ml \[1-^14^C\] palmitic acid to the samples which were incubated for 1 hr at 37°C in eppendorf tubes with a Whatman paper circle in the cap. The reaction was stopped by adding 300 μl of 3 M perchloric acid and 1 M NaOH was added to impregnate the Whatman cap. After 2 hr the Whatman caps were retired and the radioactivity associated was measured in a scintillation counter. The eppendorf tubes were centrifugated at 21.000 xg 10 min at 4°C. Four hundred μl from the supernatant were collected and the radioactivity was counted in a scintillation counter. The supernatant contained the acid soluble metabolites (ASM) and the Whatman caps captured the released CO~2~.

### Measurements of oxygen consumption rate {#sec4.4.15}

The respiration of primary hepatocytes, intact BAT, and liver and BAT mitochondria was measured at 37°C by high-resolution respirometry with the Seahorse Bioscience XF24-3 Extracellular Flux Analyzer. For the measurement of the oxygen consumption rate (OCR), as the rate change of dissolved O~2~, primary mouse hepatocytes were seeded respectively in a collagen I coated XF24 cell culture microplate (Seahorse Bioscience; Agilent Technologies; Santa Clara, CA, US), at 2.0 × 10^4^ cells/well. After 2 hr of plating, growth medium was removed and replaced with 500 μL of assay medium pre-warmed to 37°C, composed of DMEM without bicarbonate containing 1 mM sodium pyruvate, 2 mM L-glutamine, and cultured at 37°C in room air. Basal measurements of OCR were performed after equilibration in assay medium for 1h. The normalized data were expressed as pmol of O~2~/minute/μg protein for primary hepatocytes. OCR in BAT was measured short after sacrifice and small pieces of tissue were seeded in Seahorse plates with the above-mentioned assay medium and trapped using islet capture microplates provided by the company. At the end of experiment, OCR values were normalized to protein tissue content. For mitochondrial respiration experiments, liver and BAT mitochondria were isolated by a method similar to Schnaitman and Greenawalt ([@bib45]) and basal respiration measurements were made in the presence of succinate and rotenone. The normalized data were expressed as pmol of O~2~/minute/μg protein for isolated mitochondria.

### Electron microscopy and stereological analysis {#sec4.4.16}

For electron microscopy experiments, small pieces of BAT samples (1 mm^3^) were fixed with 1% glutaraldehyde/2% paraformaldehyde in 0.1 M cacodylate buffer for 6-8 hr at 4°C and postfixed with 1% OsO~4~ in 0.1 M cacodylate buffer (2 hr at 4°C). Samples were then dehydrated and embedded in EMbed 812 resin (Electron Microscopy Sciences, Hatfield, PA, USA) for 48 hr at 65°C. After trimming, resin blocks were sectioned in an Ultracut Reicher Ultramicrotome to obtain ultrathin (40-60 nm) sections, which were contrasted with 2% uranyl acetate for 7 min, and 3% lead citrate for 6 min at 37°C and in the absence of CO~2~. Samples were visualized in a JEOL JEM-1400 Transmission Electron Microscope (Jeol; Peabody, MA, USA) by a blinded investigator. Between 5 and 10 high resolution images/animal (n = 4) and experimental condition were acquired and processed using ImageJ 1.44 software (NIH; Bethesda, MD, USA). Briefly, mitochondrial and lipid droplet ultrastructure and stereology were assessed from low-magnification micrographs (4,000 X) containing whole brown adipocytes, from which planimetric parameters (lipid droplet and mitochondria number/area unit, area, and circularity coefficient) were calculated. For planimetric measurements more than 2,000 lipid droplets and 10,000 mitochondria/experimental group were scored. Lipid droplet and mitochondria size frequency distributions were calculated using the total number of organelles visualized/experimental condition.

### Blood biochemistry {#sec4.4.17}

The blood of the animals was collected in specific tubes (BD Vacutainer; Plymouth, UK) and centrifuged during 15 min at 2000 xg to separate the serum. Levels of TSH, T3 and T4 were measured using rat ELISA kits (Crystal Chem; Downers Grove IL, USA) ([@bib28], [@bib54]). Serum levels of FGF21 were measured using a rat kit (Biovendor; Karasek, Czech Republic). Ketone bodies were quantified using a commercially available kit from Wako Chemicals GmbH (Richmond, VA, USA). All measurements were done following the manufacturer's instructions specifically.

### Fatty acid analysis {#sec4.4.18}

Total lipids were extracted from 15 mg of frozen liver tissue using a modified Folch extraction method. Deuterated tridecanoic acid (C13D25O2H, Cambridge Isotopes; Andover, MA, USA) was used as internal standard. Total lipids were saponified and derivatized into fatty acid methyl esters using boron trifluoride ([@bib35]). Samples were resuspended in hexane and analyzed on a Thermo Finnigan Focus GC coupled to a FID detector. A Thermo Scientific TR-FAME column (length: 30 m, inter diameter: 0.25 mm, film size: 0.25 μm; Thermo Scientific; Surrey, UK) was used with helium as carrier gas at 1.9 ml/min. Inlet temperature was 230°C and detector temperature was 250°C. Temperature program was as follows: 100°C for 2 min, 25°C/min for 2 min, 2.5°C/min for 4.8 min, hold for 3.8 min, 4.5°C/min for 2.4 min, hold for 5 min, 5°C/min for 7.4 min, 40°C/min for 0.5 min and hold for 0.5 min. Chromatograms were analyzed and quantified using Xcalibur 2.0 (Thermo Scientific; Surrey, UK). Identification of FAME peaks was made by comparing retention times against external standards (Restek 35077 Food industry FAME mix; Bellefonte, PA, USA; and Supelco 46904 Vaccenic Methyl ester; Sigma-Aldrich, St Louis, MO, USA). Data were normalized to internal standard and followed by adjustment for tissue weight. Results are expressed as molar percentages normalized to control animals.

### TLC separation of lipids for ^14^C experiments {#sec4.4.19}

Extracted total lipids were resuspended in chloroform and spotted onto TLC plates (Plastic Backed Silica Matrix, Merck; Hoddesdon, UK) for separation of TG and FA. Chromatography was performed using toluene:chloroform:methanol (85:15:5) as the migrating solvent. Lipid bands were visualized using a primuline solution and scraped into scintillation vials for ^14^C quantification once plates had dried.

### Calculation of ^14^C specific activity {#sec4.4.20}

Tissue/serum lysates or lipid extracts were resuspended in Beta-Fluor Scintillans (National Diagnostics; Atlanta; USA) and decays/min measured using a scintillation counter (LabLogic 300SL, LabLogic; Broomhill, UK).

### Ceramide quantification {#sec4.4.21}

Ceramides were extracted and analyzed using liquid chromatography-mass spectrometer consisted of a Waters Acquity UPLC System connected to a Waters LCT Premier Orthogonal Accelerated Time of Flight Mass Spectrometer (Waters; Millford, MA, USA), operated in positive electrospray ionization mode. Full scan spectra from 50 to 1500 Da were acquired and individual spectra were summed to produce data points each 0.2 s. Mass accuracy and reproducibility were maintained by using an independent reference spray by the LockSpray interference. The analytical column was a 100 mmL 2.1 mm i.d., 1.7 mm C8 Acquity UPLC BEH (Waters; Millford, MA, USA). The two mobile phases were phase A: methanol; phase B: water, both contained 0.2% formic acid (v/v) and 2 mM ammonium formate. A linear gradient was programmed (0.0 min: 20% B; 3 min: 10% B; 6 min: 10% B; 15min: 1% B; 18 min: 1% B; 20 min: 20% B; 22 min: 20% B). The flow rate was 0.3 mL/min. The column was held at 30°C. Quantification was carried out using the extracted ion chromatogram of each compound, using 50 mDa windows. The linear dynamic range was determined by injecting standard mixtures. Positive identification of compounds was based on the accurate mass measurement with an error \< 5 ppm and its LC retention time, compared to that of a standard (±2%). Concentrations were measured by multiple reaction monitoring experiments using N-lauroyl-D-erythro-sphingosine (C12-ceramide) and N-Heptadecanoyl-D-erytro-Sphingosine (C17-ceramide) as internal standards and using as patrons N-Palmitoyl-D-erytro-sphingosine (C16-ceramide), N-Stearoyl-D-erytro-sphingosine (C18-ceramide), N-lignoceroyl-D-erythro-sphingosine (C24-ceramide) and N-nervonoyl-D-erythro-sphingosine (C24:1-ceramide) (Avanti Polar Lipids; Alabaster, AL, USA). The ceramide analyses were performed in the Research Unit on Bioactive Molecules (RUBAM) of the Institut de Química Avançada de Catalunya (IQAC-CSIC).

### Lipidomics {#sec4.4.22}

#### Sample preparation {#sec4.4.22.1}

Hypothalami were dissected weighed and 20 μL of an internal standard mixture and 100 μL of NaCl (0.9%) were added to the sample. Lipids were extracted from the samples with 400 μL of chloroform:methanol (2:1) solvent and the tissue was homogenized. After vortexing for 2 min and incubating for 1 hr at room temperature, the lower layer (approximately 100 μL) was separated by centrifugation at 10,000 rpm for 3 min at room temperature. Ten μL of labeled standard mixture was added to the lipid extract. The internal standard mixture contained the following lipid compounds with heptadecanoic acid (C17:0) as the esterified fatty acid: ceramide (d18:1/17:0) (91.6 μg/mL; Avanti Polar Lipids; Alabaster, AL, USA), GPCholine (17:0/17:0) (9.9 μg/mL; Avanti Polar Lipids; Alabaster, AL, USA), GPEthanolamine (17:0/17:0) (89.5 μg/mL; Avanti Polar Lipids; Alabaster, AL, USA) and TG (17:0/17:0/17:0) (103.6 μg/mL; Larodan Fine Chemicals; Limhamn, Sweden). The labeled standard mixture consisted of GPCholine (16:0/0:0-D3) (92.8 μg/mL; Larodan Fine Chemicals, Limhamn, Sweden), GPCholine (16:0/16:0-D6) (116.8 mg/mL; Larodan Fine Chemicals, Limhamn, Sweden) and TG (16:0/16:0/16:0-^13^C3) (99.6 μg/mL; Larodan Fine Chemicals, Limhamn, Sweden).

#### Lipidomic analysis {#sec4.4.22.2}

Lipid extracts were analyzed at VTT Technical Research Centre of Finland (Espoo, Finland) on a Q-ToF Premier mass spectrometer (Waters; Milford, MA, USA) combined with an Acquity Ultra Performance Liquid chromatography (UPLC/MS; Chicago, IL, USA). The column was an Acquity UPLC BEH C18 10x50 mm with 1.7 μm particles and kept at 50°C. The binary solvent system A included water (1% 1M NH~4~Ac, 0.1% HCOOH) and solvent system B included LC/MS grade acetonitrile/isopropanol (5:2, 1% 1M NH~4~Ac, 0.1% HCOOH) (Rathburn; Walkerburn, UK). The gradient started from 65% A/ 35% B, reached 100% B in 6 min and remained there for the next 7 min. The total run time including a 5 min re-equilibration step was 18 min. The flow rate was 0.2 mL/min and injection volume 1 μL. The temperature of the sample organizer was set at 10°C. The lipid profiling was carried out using positive ion mode. The data was collected at mass range of m/z 300-2000 with scan duration of 0.2 s. The source temperature was set at 120°C and nitrogen was used as desolvation gas (800 L/h) at 250°C. The voltages of the sampling cone and capillary were 39 V and 3.2 KV, respectively. Reserpine (50 μg/L) was used as the lock spray reference compound (5 μL/min; 10 s scan frequency).

#### Lipidomic data processing and analysis {#sec4.4.22.3}

The obtained data was converted into netCDF file format using Dbridge Software from MASSLYNX (Waters; Milford, MA, USA). The converted data was processed using MZmine Software version 0.60. Lipids were identified based on their retention time (RT) and mass to charge ratio (MZ) using our in-house built lipid database. All the identified lipids were quantified by normalizing with corresponding internal standards. All monoacyl lipids except cholesterol esters, such as monoacylglycerols and monoacyl-glycerophospholipids were normalized with GPCho (17:0/0:0). All diacyl lipids, except ethanolamine phospholipids, were normalized with GPCho (17:0/17:0). The diacyl ethanolamine phospholipids were normalized with GPEth (17:0/17:0) and the triacylglycerols and cholesterol esters normalized with TG (17:0/17:0/17:0).

### Immunohistochemistry {#sec4.4.23}

Enzymatic immunohistochemistry was performed as previously described ([@bib28], [@bib54], [@bib31]), using a rabbit anti-c-FOS (Santa Cruz Biotechnology, CA, USA). After perfusion of the animals through the ascending aorta with 150 mL 0.9% NaCl, followed by 500 mL of 4% formaldehyde in 100 mM phosphate buffer (PB), pH 7.4, under deep anesthesia with ketamine-xylazine. The tissues were fixed in 10% buffered formaldehyde and subsequently treated for histological study by dehydration (increasing alcohol concentrations), mounting in xylene and immersion in paraffin. The paraffin blocks were sliced into 3 μm sections that were processed, deparaffinized in xylene, rehydrated and rinsed in distilled water, then stained with the specific primary antibody and incubated overnight, washed and incubated with the secondary antibody (Dako EnVision system, peroxidase; Glostrup, Denmark). c-FOS positive cells were counted by using ImageJ-1.33 (NIH; Bethesda, MD, USA). Seven-11 bilateral image sections per animals were analyzed. Direct detection of GFP fluorescence was performed after perfusion of the animals; on 40 μm sections. Images were taken with a fluorescence microscope Olympus IX51 (Olympus Corporation; Tokyo, Japan).

Hepatic lipid content was analyzed by Red Oil O staining as previously shown ([@bib21], [@bib10], [@bib32]). Hepatic frozen sections were cut (8 μm) and fixed in 10% buffered formaldehyde. Sections were stained in filtered Oil Red O (Sigma-Aldrich; St. Louis, MO, USA), washed in distilled water, counterstained with Harris hematoxylin (Bio-Optica; Milan, Italy) and washed in distilled water again. Sections were mounted in aqueous mounting medium (Bio-Optica; Milan, Italy). Images were taken with a digital camera Olympus XC50 (Olympus Corporation; Tokyo, Japan) at 20x (for rats) and 40x (for mice). Digital images for liver were quantified with ImageJ-1.33 (NIH; Bethesda, MD, USA).

### In situ hybridization {#sec4.4.24}

Coronal brain sections (16 μm) were cut on a cryostat and immediately stored at −80°C until hybridization. In situ hybridization was performed as previously described ([@bib28], [@bib31]). Sections were probed with a specific oligonucleotide for TRH (*Trh*; GenBank: [NM_013046](ncbi-n:NM_013046){#intref0250}; 5′- ATA CCA GTT AGG GTG AAG ATC AAA GCC AGA GCC AGC AGC AAC CAA--3') or AMPKα1 (*Prkaa1*; GenBank: [NM_001013367](ncbi-n:NM_001013367){#intref0255}; 5′- GCT CTC CTC CAG AGA CAT ATT CCA TCA CCA TGA-3′). These probes were 3′ end labeled with ^35^S-αdATP (Perkin Elmer, Waltham, MA, USA) using terminal deoxynucleotidil transferase (New England Biolabs; Ipswich, MA). The specificity of the probes was confirmed by incubating the sections with an excess of the unlabeled probes. The frozen sections were fixed with 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4) at room temperature for 30 min. They were then dehydrated using 70, 80, 90, 95%, and absolute ethanol (5 min each). The hybridization was carried out overnight at 37°C in a moist chamber. Hybridization solution contained 0.5x10^6^ cpm (for both TRH and AMPKα1) per slide of the labeled probe, 4X saline-sodium citrate buffer (SSC), 50% deionized formamide, 1X Denhardt\'s solution, 10% dextran sulfate and 10 μg/ml sheared, single-stranded salmon sperm DNA (all of them, Sigma-Aldrich; St. Louis, MO, USA). Afterward, the hybridization sections were sequentially washed in 1X SSC at room temperature, four times in 1X SSC at 42°C (30 min per wash), one time in 1X SSC at room temperature (1 h), and then rinsed in water and ethanol. Finally, the sections were air-dried and exposed to Hyperfilm β-Max (KODAK; Rochester, NY, USA) at room temperature for 7 days for TRH and 14 days for AMPKα1. The slides from all experimental groups were exposed to the same autoradiographic film and then they were developed in developer/replenisher (Developer G150, AGFA HealthCare: Mortsel, Belgium) and fixator (Manual Fixing G354; AGFA HealthCare: Mortsel, Belgium). Sections were scanned and the hybridization signal was quantified by densitometry using ImageJ-1.33 software (NIH; Bethesda, MD, USA). The optical density of the hybridization signal was determined and subsequently corrected by the optical density of its adjacent background value. A rectangle, with the same dimensions in each case, was drawn enclosing the hybridization signal over each nucleus and over adjacent brain areas of each section (background) ([@bib28], [@bib31]). Sixteen-20 sections for each animal (4-5 slides with 4 sections/slide) were used. The mean of these 16-20 values was used as densitometry value for each animal.

### Real-time quantitative RT-PCR {#sec4.4.25}

Real-time PCR (TaqMan; Applied Biosystems; Foster City, CA, USA) was performed using specific primers and probes ([Table S1](#mmc1){ref-type="supplementary-material"}) as previously described ([@bib28], [@bib31], [@bib32]). Total RNA was isolated by using Trizol Reagent (Invitrogen; Carlsbad, CA, USA) according to the manufacturer's protocol (RNA was precipitated with chloroform and isopropanol, washed with 75% ethanol, and finally dissolved in RNase-free water). cDNA synthesis was performed with M-MLV enzyme (Invitrogen; Carlsbad, CA, USA) following the supplier's protocol. All reactions were carried out using the following cycling parameters: 50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s, 60°C for 1 min. Values were expressed in relation to hypoxanthine-guanine phosphoribosyl-transferase (*Hprt*) levels.

### Western blotting {#sec4.4.26}

Protein lysates from hypothalamus (total, MBH or VMH), liver, muscle, WAT and BAT were homogenized in lysis buffer (consisting of a mix of 0.05 M Tris-HCl, 0.01 M EGTA, 0.001 M EDTA, 0.016 M Triton X-100, 0.001 M sodium orthovanadate, 0.05 M sodium fluoride, 0.01 M sodium pyrophosphate and 0.25 M sucrose, made up with distilled water and adjusted to 7.5 pH; all of them from Sigma-Aldrich; St. Louis, MO, USA) and freshly added protease inhibitor cocktail tablets (Roche Diagnostics; Indianapolis, IN, USA). The protein concentration was determined by the Bradford Method (Protein assay dye concentrate, Bio-Rad Laboratories; Hercules, CA, USA), and the total protein content of the tissues was calculated. The protein lysates were subjected to SDS-PAGE, electrotransferred to polyvinylidene difluoride membranes (PVDF; Millipore; Billerica, MA, USA) with a semidry blotter and probed with antibodies against ACC, AMPKα1, AMPKα2 (Millipore; Billerica, MA, USA), GRP78, IREα, pACCα (Ser79), pAMPKα (Thr172), p-c-Jun (Ser63), pHSL (Ser660), PERK, pJNK (Thr183/Tyr185), pSTAT3 (Ser727) (Cell Signaling; Danvers; MA, USA); FAS (BD; Franklin Lakes, NJ, USA); ATF6α, CHOP, JNK1/3, NFκB p65, peIF2α (Ser52), p-IKKα/β, pPERK (Thr981), PKCδ (Santa Cruz; Santa Cruz, CA,USC); HSL, pIREα (Ser724), PKCε, SPTLC1, SPTLC2, UCP1, UCP3 (Abcam; Cambridge, UK); α-tubulin or β-actin (Sigma-Aldrich; St. Louis, MO, USA) as described ([@bib28], [@bib54], [@bib31], [@bib10], [@bib32]). Each membrane was then incubated with the corresponding secondary antibody: anti-mouse, anti-rabbit or anti-goat (all of them from DAKO; Glostrup, Denmark). The membranes were exposed to an X-ray film (Fujifilm; Tokyo, Japan) and developed using developer (Developer G150; AGFA HealthCare: Mortsel, Belgium) and Fixator (Manual Fixing G354; AGFA HealthCare: Mortsel, Belgium).

Autoradiographic films were scanned and the bands signal was quantified by densitometry using ImageJ-1.33 software (NIH; Bethesda, MD, USA). Values were expressed in relation to β-actin (hypothalamus, liver and WAT) or α-tubulin (muscle and BAT). In [Figure 1](#fig1){ref-type="fig"}A data are expressed as a percentage of vehicle ICV for each tissue. Representative images for all proteins are shown; in the case of the loading controls a representative gel is displayed, although each protein was corrected by its own internal control (β-actin or α-tubulin), as explained above. In all the Figures showing images of gels, all the bands for each picture come always from the same gel, although they may be spliced for clarity. In the ACC westerns, the bands represent ACCα for liver, WAT and BAT and ACCβ for the muscle. In the pACC westerns, the upper band corresponds to pACCβ and the lower band to pACCα.

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

ImageJ-1.33 software (NIH; Bethesda, MD, USA) was used to count c-FOS positive cells and to process electron microscopy, western blot analyses and in situ hybridization and liver histologic images ([@bib28], [@bib54], [@bib31], [@bib10], [@bib32]). Statistical analysis was conducted using GraphPad Prism 6 Software (GraphPad Software; La Jolla, CA, USA). Data are expressed as mean ± SEM as percentage of stained area in the image of the appropriate controls (euthyroid, vehicle-treated, GFP, sham-vehicle rats or WT mice). Error bars represent SEM. Statistical significance was determined by t-Student (when two groups were compared) or ANOVA (when more than two groups were compared) followed of post hoc two-tailed Bonferroni test. p \< 0.05 was considered significant. The number of animals used in each experimental setting and analysis are specified in each Figure Legend.
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